Augmentation of clozapine with ziprasidone in refractory schizophrenia: A double-blind, placebo-controlled study

Journal of Clinical Psychopharmacology

Volumn 34, Issue 1, 2014, Pages 129-133

  Muscatello, Maria Rosaria A ^a   Pandolfo, Gianluca ^a   Micò, Umberto ^a   Lamberti Castronuovo, Eduardo ^b   Abenavoli, Elisabetta ^a   Scimeca, Giuseppe ^a   Spina, Edoardo ^c   Zoccali, Rocco ^a   Bruno, Antonio ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b Sezione di Cardiologia e Riabilitazione Cardiologica   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

Author keywords

Augmentation; Clozapine; Schizophrenia; Treatment resistant; Ziprasidone

Indexed keywords

CLOZAPINE; PLACEBO; ZIPRASIDONE;

ABNORMAL BLOOD PRESSURE; ADD ON THERAPY; ADULT; AKATHISIA; ARTICLE; BLOOD PRESSURE; BODY TEMPERATURE; BODY TEMPERATURE DISORDER; BREATHING DISORDER; BREATHING RATE; BRIEF PSYCHIATRIC RATING SCALE; CALGARY DEPRESSION SCALE; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART DISEASE; HEART RATE VARIABILITY; HEMATOLOGIC DISEASE; HEMATOLOGICAL PARAMETERS; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MONOTHERAPY; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SEIZURE; SEMANTICS; STEADY STATE; STROOP TEST; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WISCONSIN CARD SORTING TEST; YOUNG ADULT;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COGNITION; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; ITALY; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84891740629     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000042     Document Type: Article

References (28)

1. Gallego JA, Bonetti J, Zhang J, et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012;138:18-28.
2. Taylor DM, Smith L, Gee SH, et al. Augmentation of clozapine with a second antipsychoticVa meta-analysis. Acta Psychiatr Scand. 2012;125:15-24.
3. Porcelli S, Balzarro B, Serretti A. Clozapine resistance: augmentation strategies. Eur Neuropsychopharmacology. 2012;22:165-182.
4. Assion HJ, Reinbold H, Lemanski S, et al. Amisulpride augmentation in patients with schizophrenia partially responsive or unresponsive to clozapine. A randomized, double-blind, placebo-controlled trial. Pharmacopsychiatry. 2008;41:24-28.
5. Weiner E, Conley RR, Ball MP, et al. Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology. 2010;35:2274-2283.
6. Muscatello MR, Bruno A, Pandolfo G, et al. Effect of aripiprazole augmentation of clozapine in schizophrenia: a double-blind, placebo-controlled study. Schizophr Res. 2011;127:93-99.
7. Nielsen J, Emborg C, Gydesen S, et al. Augmenting clozapine with sertindole: a double-blind, randomized, placebo-controlled study. J Clin Psychopharmacol. 2012;32:173-178.
8. Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther. 2002;24:21-37.
9. Rollema H, Lu Y, Schmidt AW, et al. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol Psychiatry. 2000;48:229-237.
10. Ziegenbein M, Calliess IT. Clozapine and ziprasidone: a useful combination in patients with treatment-resistant schizophrenia. J Neuropsychiatry Clin Neurosci. 2006;18:246-247.
11. Ziegenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol. 2005;28:220-224.
12. Zink M, Mase E, Dressing H. Combination of ziprasidone and clozapine in treatment-resistant schizophrenia. Hum Psychopharmacol. 2004;19:271-273.
13. Kaye NS. Ziprasidone augmentation of clozapine in 11 patients. J Clin Psychiatry. 2003;64:215-216.
14. Henderson DC, Fan X, Copeland PM, et al. Ziprasidone as an adjuvant for clozapine-or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol. 2009;24:225-232.
15. Zink M, Kuwilsky A, Krumm B, et al. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol. 2009;23:305-314.
16. Daniel DG, Zimbroff DL, Potkin SG, et al. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20(5):491-505.
17. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
18. Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand. 2004;110:292-298.
19. Leucht S, Kane JM, Kissling W, et al. Clinical implications of Brief Psychiatric Rating Scale scores. Br J Psychiatry. 2005;187:366-371.
20. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems; 1986.
21. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl. 1993;33:39-44.
22. Heaton R, Chelune G, Talley J, et al. Wisconsin Card Sorting Test Manual. Odessa, FL: Psychological Resources; 1993.
23. Spreen O, Strauss E. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary. 2nd ed. New York, NY: Oxford University Press; 1998.
24. renerry MR, Crosson B, DeBoe J, et al. Stroop Neuropsychological Screening Test. Odessa, FL: Psychological Assessment Resources Inc; 1989.
25. Avenoso A, Facciola G, Campo GM, et al. Determination of clozapine, N-desmethylclozapine, and clozapine N-oxide in human plasma by reverse phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Appl. 1998;714:299-308.
26. Harvey PD, Sacchetti E, Galluzzo A, et al. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. Schizophr Res. 2008;105:138-143.
27. Cana F. Mechanisms of action of atypical antipsychotics. CNS Spectr. 2005;10:5-11.
28. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005;162:441-449.